Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share

Humacyte, Inc.

Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.
Underwriters have 30-day option to buy up to 2,010,000 additional shares.
Net proceeds ~$37.4M (or ~$43.1M if option exercised); closing expected March 5, 2024.
Proceeds to fund BLA for HAVs in vascular trauma, pipeline advancement, and commercial infrastructure.
TD Cowen and Cantor are joint book-running managers; BTIG is lead manager.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Humacyte, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein valued at approximately $37.4 million (effective 2024-02-29).

Action: entry
Agreement: underwriting
Counterparty: Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein
Value: approximately $37.4 million
Effective: 2024-02-29

Exact text from the filing

On February 29, 2024, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) of 13,400,000 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $3.00 per share (the “Firm Shares”).

View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-24-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.